OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.

Kathryn EvansJianXin DuanTara PritchardConnor D JonesLisa McDermottZhaohui GuCara E ToscanNarimanne El-ZeinChelsea MayohStephen W EricksonYuelong GuoFanying MengDonald JungKomal S RathiKathryn G RobertsCharles G MullighanChi-Sheng ShiaTillman PearceBeverly A TeicherMalcolm A SmithRichard B Lock

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

OBI-3424 exerted profound in vivo efficacy against T-ALL PDXs derived predominantly from aggressive and fatal disease, and therefore may represent a novel treatment for aggressive and chemoresistant T-ALL in an AKR1C3 biomarker-driven clinical trial.

Keyphrases

clinical trial
intellectual disability
cancer therapy
randomized controlled trial
mesenchymal stem cells
anti inflammatory
open label
autism spectrum disorder
drug delivery
bone marrow
african american
smoking cessation